Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients.
The effects of metformin on the fibrinolytic system were studied pre- and post-venous occlusion in 38 Type 2 diabetic patients in a double-blind, placebo-controlled trial. After a 3-week run-in period, 21 patients received metformin and 17 placebo, for 6 weeks. In the metformin-treated patients basal plasminogen activator inhibitor-1 antigen (PAI-1Ag) fell from 57.4 micrograms l-1 before treatment to 36.1 (p less than 0.05) and 41.0 micrograms l-1 (p less than 0.01) after 3 and 6 weeks therapy. In this group post-venous occlusion PAI-1Ag also fell after 3 weeks (p less than 0.002) and 6 weeks (p less than 0.05) treatment. There were no changes in either basal or post-venous occlusion concentrations of PAI-1Ag in the placebo treated group. The fall in PAI-1Ag was not associated with an increase in basal plasminogen activator activity (PAA) which remained unchanged in both groups. Post-venous occlusion values for PAA in the metformin treated patients were increased at 3 weeks (p less than 0.05) although there was no difference at 6 weeks.
Grant
P J
PJ
University Department of Medicine, Leeds, UK.
Stickland
M H
MH
Booth
N A
NA
Prentice
C R
CR
D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D003927:Diet, Diabetic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D005905:Glyburide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000097:blood*; D014680:Veins / Q000503:physiopathology*; D000511:alpha-Macroglobulins / Q000032:analysis
D001786:Blood Glucose; D005341:Fibrinolysin; D005905:Glyburide; D006442:Glycated Hemoglobin; D008687:Metformin; D015849:Plasminogen Inactivators; D000511:alpha-Macroglobulins; C024668:plasmin-alpha(2)-macroglobulin complex